Clinical Trial

A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 18, 2023 (before its estimated April 14, 2024 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to evaluate the efficacy, safety and immunogenicity of a live attenuated varicella vaccine manufactured by Beijing Institute of Biological Products Co., Ltd in healthy children.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-12-20; most recent amendment 2023-06-15.
Status change: Recruiting → Active, Not Recruiting 2023-06-15
Status change: Not Yet Recruiting → Recruiting 2023-01-18
Trial Details
NCT Number NCT05669625
Lead Sponsor China National Biotec Group Company Limited
Collaborators: Beijing Institute of Biological Products Co Ltd., Jiangsu Province Centers for Disease Control and Prevention
Conditions Varicella
Enrollment 12,440 participants
Start Date 2022-12-26
Primary Completion 2024-04-14 (estimated)
Study Completion 2026-09-14 (estimated)
Updated on ClinicalTrials.gov 2023-06-18